Decentralized Manufacturing– tag –
-
Next-Gen CAR-T Manufacturing Reduces Production Time to 1-2 Days, Explores Decentralized Models for Potent Cells
Bioprocess International USA Overview An article in Bioprocess International highlights advancements in next-generation CAR-T cell therapy manufacturing, which are set to reduce production times to as little as one or two days, yielding ... -
Biomanufacturing Reorients: Geopolitical Forces Drive Sourcing to Qualified, Regional Capacity, with Cellares Pioneering IDMO Smart Factories
Pharma's Almanac USA Overview Geopolitical forces are profoundly reshaping biomanufacturing procurement, driving a surge in demand for 'qualified capacity' – providers with specialized expertise and robust regulatory compliance. This shi... -
Jordan Advances Global CAR-T Access with High-Efficiency Point-of-Care Manufacturing Using CliniMACS Prodigy
ASCO Publications Jordan Overview In a significant step towards democratizing advanced cell therapies, point-of-care manufacturing of anti-CD19.1 CAR-T cells using the Miltenyi CliniMACS Prodigy system was successfully demonstrated in Jo... -
Orchestrating the Next Era of Decentralized and Automated Bioprocessing: 75% Efficiency Boost in AAV Manufacturing and QC Modernization
BioPharm International USA Overview BioPharm International discussed orchestrating the next era of the biopharmaceutical industry through decentralized manufacturing models, automated AAV manufacturing, and modernizing quality control (Q...
1